Published in Clin Infect Dis on December 13, 2000
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol (2003) 1.39
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc (2013) 1.05
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays (2012) 1.04
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS (2010) 1.00
Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res (2012) 0.97
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol (2011) 0.95
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. BMC Infect Dis (2010) 0.94
Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J (2006) 0.88
Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One (2014) 0.87
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One (2010) 0.86
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Antimicrob Agents Chemother (2013) 0.83
Socio-economic- and sex-related disparities in rates of hospital admission among patients with HIV infection in Ontario: a population-based study. Open Med (2012) 0.82
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr (2014) 0.82
Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors. Med Sci Monit (2013) 0.82
Antiretroviral Therapy-associated Serious and Life-threatening Toxicities. Curr Infect Dis Rep (2003) 0.78
Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph? PLoS One (2014) 0.78
Sex differences in nevirapine rash. Clin Infect Dis (2001) 0.78
Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr (2010) 0.78
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother (2014) 0.77
Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity. Curr Infect Dis Rep (2005) 0.77
Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75
Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study. Curr Ther Res Clin Exp (2008) 0.75
Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria. Ghana Med J (2014) 0.75
A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation. Open AIDS J (2009) 0.75
The Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations. Infect Dis Obstet Gynecol (2015) 0.75
Renal histoarchitectural changes in nevirapine therapy: possible role of kolaviron and vitamin C in an experimental animal model. Afr Health Sci (2017) 0.75
Community-acquired pneumonia. N Engl J Med (1995) 6.12
Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) (2005) 6.10
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis (2000) 3.12
Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis (1999) 3.12
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Reassessing the role of epidemiology in public health. Am J Public Health (1999) 2.20
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08
Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis (2000) 1.95
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection (2007) 1.72
Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant (2006) 1.67
Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord (2007) 1.67
Spatial analysis and mapping of sexually transmitted diseases to optimise intervention and prevention strategies. Sex Transm Infect (2004) 1.66
Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol (1999) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun (1997) 1.58
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
Sexually transmitted disease acquisition among women infected with human immunodeficiency virus type 1. J Infect Dis (1998) 1.43
HIV and cardiovascular risk factors. AIDS Read (2001) 1.40
Non-neoformans cryptococcal infections: a systematic review. Infection (2007) 1.39
The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care (2006) 1.39
Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett (1994) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Can we do better than discrepant analysis for new diagnostic test evaluation? Clin Infect Dis (1998) 1.37
Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis (2000) 1.34
Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol (1997) 1.34
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
Quality of life instruments and definitions in individuals with spinal cord injury: a systematic review. Spinal Cord (2009) 1.27
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
Evaluation of a latex agglutination test for Clostridium difficile in two nursing home outbreaks. J Clin Microbiol (1989) 1.20
Diagnosis of Chlamydia pneumoniae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis (1994) 1.18
Concordance of chlamydia trachomatis infections within sexual partnerships. Sex Transm Infect (2007) 1.16
Smoke inhalation in firemen. Thorax (1980) 1.16
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. J Clin Microbiol (2001) 1.14
Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.13
Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand. HIV Med (2008) 1.13
Measuring nitric oxide production in human clinical studies. Methods Enzymol (1999) 1.13
Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis (2000) 1.12
Trends of gonorrhea and chlamydial infection during 1985-1996 among active-duty soldiers at a United States Army installation. Clin Infect Dis (2000) 1.12
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med (2000) 1.11
Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol (1995) 1.10
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med (1998) 1.09
Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1992) 1.09
Adaptations to a high-fat diet that increase exercise endurance in male rats. J Appl Physiol Respir Environ Exerc Physiol (1984) 1.09
Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis (1995) 1.07
Biopersistence of synthetic vitreous fibers and amosite asbestos in the rat lung following inhalation. Toxicol Appl Pharmacol (1998) 1.06
Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.06
A review of instruments assessing participation in persons with spinal cord injury. Spinal Cord (2009) 1.05
LCR testing for gonorrhoea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. Sex Transm Infect (2003) 1.05
Exposure of mice to live Pseudomonas aeruginosa generates protective cell-mediated immunity in the absence of an antibody response. J Immunol (1988) 1.05
Evaluation of the BOD POD for estimating percentage body fat in a heterogeneous group of adult humans. Eur J Appl Physiol (2001) 1.04
Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin Infect Dis (2001) 1.04
A systematic review of depression and anxiety measures used with individuals with spinal cord injury. Spinal Cord (2009) 1.03
Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis (1999) 1.02
Pneumococcal endocarditis: report of a series and review of the literature. Rev Infect Dis (1986) 1.02
Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS (1999) 1.01
Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol (1980) 1.01
Disclosure of HIV status to medical providers: differences by gender, "race," and immune function. Public Health Rep (2000) 1.01
Tuberculin reactivity in bacille Calmette-Guérin vaccinated populations: a compilation of international data. Int J Tuberc Lung Dis (2006) 1.01
Mechanisms of oxygen effects on exercise in patients with chronic obstructive pulmonary disease. Chest (1982) 1.01
Respiratory failure in cancer patients. JAMA (1979) 1.00
Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.00
Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect (2009) 1.00
Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS (2000) 1.00
Clinical correlates of fatigue in spinal cord injury. Spinal Cord (2007) 1.00
Variations in healthcare measures by insurance status for patients receiving ventilator support. Clin Perform Qual Health Care (1998) 1.00
An evidence-based review of aging of the body systems following spinal cord injury. Spinal Cord (2010) 0.98
Isoelectric point of albumin: effect on renal handling of albumin. Kidney Int (1979) 0.97
Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis (1994) 0.97
Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race. HIV Med (2010) 0.96
Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis (2012) 0.96
T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice. J Clin Invest (1986) 0.96
Fellowship training in infectious diseases: a report from the regional and national meetings of infectious diseases division chiefs and program directors. Clin Infect Dis (1998) 0.96
Contraceptive use and pregnancy decision making among women with HIV. AIDS Patient Care STDS (1999) 0.96
Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol (1985) (2001) 0.95
Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun (1995) 0.95
Are all recently detoxified alcoholics depressed? Am J Psychiatry (1979) 0.95
The relationship between and predictors of quality of life after spinal cord injury at 3 and 15 months after discharge. Spinal Cord (2009) 0.94
Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine (2011) 0.94